DGAP-News

Biotest AG: Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors - Seite 2

the Phase IIa part, indatuximab ravtansine (BT-062) is being administered
at its MTD to further assess its safety and efficacy in the mentioned
indications.

The study is funded by Cluster for Individualized ImmunIntervention (Ci3)
Mainz, Germany.

About indatuximab ravtansine (BT-062):

Indatuximab ravtansine (BT-062) is an antibody drug conjugate consisting of
a monoclonal antibody and a highly potent cytotoxic maytansine derivative
(DM4) using the antibody-drug conjugate (ADC) technology developed by
ImmunoGen, Inc. The antibody binds specifically to the antigen CD138, which
is over-expressed on multiple myeloma cells and a variety of solid tumors.

Once the conjugate is internalised into the target cell, the cytotoxic
agent DM4 is released from the targeting molecule by lysosomal degradation.
Thus, the conjugation of DM4 to the antibody keeps the cytotoxic moiety
inactive until it is released within the CD138 expressing target cell. This
combination of high efficacy and specificity with low systemic toxicity
sets indatuximab ravtansine (BT-062) apart from most therapies currently
used to treat malignancies.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 2,000
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.